Shijiyao Group(02005) divulga resultados anuais Lucro líquido de aproximadamente HKD 471 milhões, uma redução de 55,6% em relação ao ano anterior. Dividendo final de HKD 0,03 por ação.

石四药集团(02005)发布截至2025年12月31日止财政年度全年业绩，
A Stone Four Pharmaceutical Group (02005) released its annual results for the financial year ending December 31, 2025,

2025年，在需求收缩、政策深化与行业竞争加剧的多重压力下，
In 2025, under multiple pressures of demand contraction, deepening policies, and intensified industry competition,

集团主要经济指标承受了近年来前所未有的下行压力，
the group’s main economic indicators faced unprecedented downward pressure in recent years,

经历了极为严峻的考验。
and underwent extremely severe tests.

面对困难，集团积极化压力为动力，以创新求变、务实进取的姿态，
In the face of difficulties, the group actively transformed pressure into motivation, adopting an innovative and pragmatic approach,

全力以赴推动企业破局前行。
and made every effort to drive the company’s breakthrough progress.

2025年全年实现销售收入以人民币计约38.12亿元，同比减少27.6%;
In 2025, the total sales revenue was approximately 3.812 billion yuan, a year-on-year decrease of 27.6%;

以港元计，全年销售收入约41.65亿港元，同比减少27.8%;
In Hong Kong dollars, the total sales revenue was approximately 4.165 billion HKD, a year-on-year decrease of 27.8%;

同期毛利率约41.6%，同比下降8.8个百分点;
The gross profit margin was approximately 41.6%, a year-on-year decrease of 8.8 percentage points;

实现净利润约4.71亿港元，同比减少55.6%。
The net profit was approximately 471 million HKD, a year-on-year decrease of 55.6%.

董事议决于2026年6月4日向于2026年5月21日名列本公司股东名册的股东派发末期息0.03港元╱股，
The board of directors resolved to distribute a final dividend of 0.03 HKD per share to shareholders listed on the company’s register on May 21, 2026, on June 4, 2026,

全年共派息0.08港元╱股，同比减少54.3%。
with a total dividend of 0.08 HKD per share for the year, a year-on-year decrease of 54.3%.

一年来，集团持续提升产品的市场可及性。
Over the past year, the group has continuously improved the market accessibility of its products.

2025年，集团克服不利因素影响，扎实做好新产品获批与各地上市准入工作的有效衔接，
In 2025, the group overcame adverse factors, effectively connecting the approval of new products with the market access work in various regions,

不失时机参与国家集采、接续及省际联盟和地方等各类药品招标活动。
and seized opportunities to participate in various pharmaceutical bidding activities at the national level, interprovincial alliances, and local levels.

全年完成42个通用名52个品规的上市准入。
Throughout the year, the group completed market access for 52 specifications of 42 generic names.

同时，全年参与国家集采接续、省际及地方联采、医疗机构等药品招标达上千次，
At the same time, the group participated in thousands of pharmaceutical bidding activities at the national level, interprovincial and local joint procurement, and medical institutions throughout the year,

尤其是在第十一批国家集采、京津冀3+N联盟带量采购接续、四川氯化钠等大容量注射液联盟带量采购、
especially in the 11th batch of national centralized procurement, the Beijing-Tianjin-Hebei 3+N alliance volume-based procurement continuation, and the large-volume injection procurement of Sichuan sodium chloride,

环磷腺苷葡胺等66个化学药品省际联盟带量联动采购、
the volume-based coordinated procurement of 66 chemical drugs such as adenosine triphosphate,

广东联盟双氯芬酸等药品集采接续采购、
the continuation of procurement for drugs like diclofenac in the Guangdong alliance,

广东联盟常见慢性病联盟接续中表现突出、中标优势明显，
and the Guangdong alliance’s performance in common chronic disease alliances was outstanding, with significant bidding advantages,

进一步夯实了重点区域的市场基础，为提升产品可及性创造了条件。
further solidified the market foundation in key areas, creating conditions for improving product accessibility.

此外，集团的国家医保目录品种日益丰富，
In addition, the variety of products in the national medical insurance catalog of the group is increasingly rich,

2025国家新版医保目录新增葡萄糖酸钙氯化钠注射液，
with the addition of calcium gluconate and sodium chloride injection in the new national medical insurance catalog of 2025,

目前集团的国家医保目录品种达201个。
bringing the total number of products in the group’s national medical insurance catalog to 201.

海量资讯、精准解读，尽在新浪财经APP
Massive information and precise interpretation, all available on the Sina Finance APP.